The drug was never the whole answer

Oura and LillyDirect, Eli Lilly's direct-to-consumer platform, announced a collaboration on 23 June to support people on GLP-1 medicines.

The headline version sounds like integrated care. The actual terms are lighter. LillyDirect customers get a free Oura Ring sizing kit. No clinical monitoring. The release is explicit that it does not involve data sharing.

I think it matters anyway. Here's why.

I spent eight years building a consumer health brand, and the lesson that took longest to land was this: getting the product onto the shelf was never the win. Getting someone to come back for the second pack was. The first purchase is a decision. The second is a habit. The gap between them is where most brands quietly die.

GLP-1 has the same problem at a much bigger scale. The prescription is the easy part. The hard part is the year after, when the novelty wears off and the result has to hold without the drug doing all the work. Sleep. Movement. Recovery. Stress. None of that comes in the injection.

Jennifer Mazur, who runs LillyDirect, framed this as caring for patients "not just at the point of prescription but in the daily moments that shape long-term success." Read that again. That's a pharma giant admitting the medication needs the rest of someone's life to work alongside it. That's the real signal. Not the ring.

The numbers tell you why these two found each other. Over half of Oura's members identify as having obesity or being overweight, and tens of thousands already log GLP-1 use in the app. Lilly, separately, says LillyDirect has made up around 45% of new prescription volume for its GLP-1s since launch. These audiences were always going to meet. The partnership just made it official.

But a sizing kit won't be what wins. Data on its own changes nothing. I learned that building a brand around a community of 100,000 women, who told us things no focus group ever would. People don't change their behaviour because a device shows them a number. They change it when the number tells them a story about themselves they want to keep living. A ring that says you slept badly is noise. A ring that shows you why this week felt easier than last week is a reason to keep going.

Here's the part almost nobody is asking. Who owns the patient relationship?

The most valuable position in this whole market isn't the molecule or the ring. It's the trusted daily relationship with the person.

I watched this exact fight in sexual health. The brand, the retailer and the platform all wanting to own the customer, because whoever owns the daily relationship owns the economics. GLP-1 is that battle at enormous scale. The drug-maker has the prescription. The wearable has the daily touchpoint. The telehealth provider has the consultation. Right now they're collaborating. They won't always. The most valuable position in this whole market isn't the molecule or the ring. It's the trusted daily relationship with the person, and everyone in the chain knows it.

There's a women's health point here that deserves more than it's getting. The trials that got these drugs approved answered whether they work. They weren't built to tell us how a GLP-1 interacts with a woman's cycle, her perimenopause, her sleep, her contraception. Women also come off these drugs at high rates, often for reasons the registration studies never centred. That real-world picture is barely mapped. Wearable data, gathered in actual lives rather than a clinical setting, is one of the few ways we start to fill it in. It's an underbuilt space, and it's where some of the most interesting work of the next few years will happen.

Which brings me to the part I find most exciting. This is a longevity story dressed as a weight-loss story. The drug is the acute intervention. The wearable layer is the joined-up view of sleep, movement and metabolic health that decides whether the result lasts. The brands that win the next decade won't sell weight loss. They'll sell the holding pattern after it. That's a harder thing to build, and a far more durable market than the prescription itself.

We're early. This is a lightweight first move, and it deserves to be read as one. But the direction is right. Holistic, data-grounded, honest that a medication is a tool and not a cure. The spend is going to follow it.

The real question isn't who makes the best ring or the best drug. It's who ends up owning the relationship with the person holding both.